Date: 2016-09-07
Type of information: Restructuring
Compound:
Company: Catalyst Biosciences (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: restructuring
Action mechanism:
Disease:
Details:
- • On September 7, 2016, Catalyst Biosciences announced that it has implemented a corporate realignment of the company's workforce, resulting in a reduction in staff of 10 employees, or approximately 50 percent.
- Catalyst Biosciences is reallocating its financial resources to its hemostasis programs to focus primarily on CB 813d, a next-generation factor VIIa for the potential treatment of hemophilia inhibitor patients and CB 2679d, a next-generation factor IX for the potential treatment of hemophilia B, both of which are expected to start clinical trials in 2017.
- Catalyst’s anti-complement research programs will be reduced and all related research activities will be discontinued. The Company will incur a one-time charge in the third quarter of approximately $1.1 million related to the reduction, including severance, benefits and related costs.
- The company intends to continue to explore licensing opportunities for its anti-complement programs in delayed graft function and dry age-related macular degeneration.
Financial terms:
Latest news:
Is general: Yes
